Amanote Research
Register
Sign In
640. AdCD40L Immunostimulatory Gene Therapy in Combination With Cyclophosphamide Prolongs 6-Months Survival in a Phase I/Ii Trial for Malignant Melanoma
Molecular Therapy
- United States
doi 10.1016/s1525-0016(16)35653-2
Full Text
Open PDF
Abstract
Available in
full text
Categories
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Date
May 1, 2014
Authors
Unknown
Publisher
Elsevier BV
Related search
AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial
Clinical Cancer Research
Cancer Research
Oncology
Nimotuzumab Prolongs Survival in Patients With Malignant Gliomas: A Phase I/Ii Clinical Study of Concomitant Radiochemotherapy With or Without Nimotuzumab
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Oncologist
Cancer Research
Medicine
Oncology
Phase I/Ii Trial of Melanoma Therapy With Dendritic Cells Transfected With Autologous Tumor-mRNA
Cancer Gene Therapy
Cancer Research
Molecular Medicine
Molecular Biology
Phase II Trial of Karenitecin in Patients With Malignant Melanoma: Clinical and Translational Study
Clinical Cancer Research
Cancer Research
Oncology
Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Gene Therapy for Pain: Results of a Phase I Clinical Trial
Annals of Neurology
Neurology
A Phase I/Ii Study of Lomustine and Temozolomide in Patients With Cerebral Metastases From Malignant Melanoma
British Journal of Cancer
Cancer Research
Oncology
Carboplatin in Combination With Epirubicin and Cyclophosphamide in Patients With Advanced Ovarian Cancer: A Phase II Study
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
